Objective To review and highlight current literature on emerging acute migraine treatments,
focusing on CGRP receptor antagonists, gepants, and 5‐HT1F receptor agonists (ditans) …

Purpose Current acute migraine treatment consists of migraine-specific agents, namely
triptans, as well as non-specific analgesia, such as non-steroidal anti-inflammatory drugs …

Introduction: Migraine afflicts approximately 11% of the population worldwide producing
substantial disability, resulting in loss of productivity both at home and at the workplace …

Introduction: Migraine is the most common of all neurological disorders. A breakthrough in
migraine treatment emerged in the early nineties with the introduction of 5-HT1B/D receptor …

Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex
pathophysiology of migraine has allowed us to make great strides in the development of …

Background: For many years triptans have been the cornerstone of acute migraine
treatment. Nevertheless, treatment with triptans may not always be initiated due to …

Triptans, serotonin 5-HT1B/1D receptor agonists, more than revolutionizing the treatment of
migraine, stimulated also ground breaking research that provided insights into the anatomy …

There now is one realized and several attractive targets for the treatment of acute attacks of
migraine that will follow and augment the use of serotonin 5-HT1B/1D receptor agonists, the …

Calcitonin gene-related peptide (CGRP) has a widespread distribution throughout the
trigeminovascular system and other brain areas involved in migraine pathogenesis. Serum …

Background The treatment of migraine is impeded by several difficulties, among which
insufficient headache relief, side effects, and risk for developing medication overuse …